<DOC>
	<DOCNO>NCT02515955</DOCNO>
	<brief_summary>The purpose study investigate safety , tolerability pharmacodynamics JNJ-54175446 multiple consecutive dose administration</brief_summary>
	<brief_title>A Study Investigate Safety , Tolerability , Pharmacokinetics , Pharmacodynamics JNJ-54175446 Healthy Male Participants</brief_title>
	<detailed_description>This randomize , placebo-and comparator-controlled , double-blind , multiple dose study JNJ-54175446 healthy male participant . The study consist Screening examination ( 28 6 day prior dose administration ) , baseline 20 mg amphetamine ( AMPH ) challenge least 5 day first dose administration , double-blind treatment period ( 18 day ; 11 day dose JNJ-54175446 , minocycline placebo ; amphetamine ( AMPH ) /AMPH placebo challenge sequence Day 7 Day 10 participant ) , follow-up examination 14 21 day last dose administration . The maximal study duration participant exceed 9 week . Safety , pharmacokinetics ( PK ) pharmacodynamics JNJ-54175446 primarily assess . Safety monitor throughout study .</detailed_description>
	<mesh_term>Amphetamine</mesh_term>
	<mesh_term>Dextroamphetamine</mesh_term>
	<mesh_term>Minocycline</mesh_term>
	<criteria>Participant must body mass index ( BMI ) 18 32 kilogram/meter^2 ( kg/m^2 ) , inclusive ( BMI = weight/height^2 ) Participants must healthy basis physical examination , medical history , vital sign , 12lead electrocardiogram ( ECG ) [ include QTcF le equal 450 millisecond ( m ) ( triplicate ECG ) ] perform screen admission clinical unit . Minor abnormality ECG , consider clinical significance investigator , acceptable . The presence Left Bundle Branch Block ( LBBB ) , atrioventricular ( AV ) Block ( second degree high ) , permanent pacemaker implantable cardioverter defibrillator [ ICD ] lead exclusion Participants must healthy basis clinical laboratory test perform screen . If result serum chemistry panel [ include liver enzymes ] , hematology , urinalysis outside normal reference range , subject may include investigator judge abnormality clinically significant . This determination must record subject 's source document initial investigator A man sexually active woman childbearing potential vasectomy must agree use barrier method birth control e.g. , either condom spermicidal foam/gel/film/cream/suppository partner occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/suppository , men must also donate sperm study 3 month receive last dose study drug . In addition , female partner also use appropriate method birth control least duration Participant history current liver renal insufficiency ; significant cardiac , vascular , pulmonary , gastrointestinal , endocrine , neurologic , hematologic , rheumatologic , psychiatric , metabolic disturbance , inflammatory illness illness Investigator considers exclude subject Participant clinically significant ( history ) psychiatric illness ( history ) psychotic symptom Participant family history relevant psychiatric disorder ( first degree ) and/or psychotic disorder ( first second degree ) Participant history hepatitis B surface antigen ( HBsAg ) hepatitis C antibody ( antiHCV ) positive , clinically active liver disease , test positive HBsAg antiHCV Screening Participant history human immunodeficiency virus ( HIV ) antibody positive , test positive HIV Screening</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Healthy</keyword>
	<keyword>JNJ-54175446</keyword>
</DOC>